C
LGND icon

Covestor’s Ligand Pharmaceuticals LGND Stock Holding History

Covestor’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$71K Sell
225
-29
-11% -$6.83K 0.04% 574
2026
Q1 		$51K Sell
254
-89
-26% -$17.6K 0.04% 704
2025
Q4 		$65K Buy
343
+341
+17,050% +$65.5K 0.03% 796
2025
Q3 		$1K Sell
2
-2
-50% -$297 ﹤0.01% 2118
2025
Q2 		$0 Sell
4
-1
-20% -$107 ﹤0.01% 2497
2025
Q1 		$1K Sell
5
-1
-17% -$113 ﹤0.01% 2022
2024
Q4 		$1K Buy
6
+1
+20% +$113 ﹤0.01% 2071
2024
Q3 		$1K Sell
5
-8
-62% -$805 ﹤0.01% 2023
2024
Q2 		$1K Hold
13
– – ﹤0.01% 2042
2024
Q1 		$1K Buy
13
+7
+117% +$516 ﹤0.01% 2018
2023
Q4 		$0 Buy
6
+1
+20% +$59 ﹤0.01% 2446
2023
Q3 		$0 Buy
5
+2
+67% +$132 ﹤0.01% 2429
2023
Q2 		$0 Hold
3
– – ﹤0.01% 2418
2023
Q1 		$0 Buy
3
+1
+50% +$71 ﹤0.01% 2328
2022
Q4 		$0 Sell
2
-1
-33% -$65 ﹤0.01% 2354
2022
Q3 		$0 Sell
3
-2
-40% -$118 ﹤0.01% 2321
2022
Q2 		$0 Hold
5
– – ﹤0.01% 2156
2022
Q1 		$0 Sell
5
-3
-38% -$218 ﹤0.01% 2291
2021
Q4 		$1K Buy
+8
New +$739 ﹤0.01% 1817

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Covestor's LGND Position: Q2 2026 in Review

Covestor reduced its Ligand Pharmaceuticals (LGND) stake by 11% in Q2 2026, selling an estimated $6.83K and leaving 225 shares worth $71K. The position accounts for 0.04% of the portfolio, ranked #574.

Covestor first reported a position in LGND in Q4 2021 and has held it in 19 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Covestor held 225 shares of Ligand Pharmaceuticals worth $71K as of Q2 2026.
  • Covestor sold 29 Ligand Pharmaceuticals shares in Q2 2026, an estimated $6.83K.
  • Ligand Pharmaceuticals made up 0.04% of Covestor's portfolio in Q2 2026, its #574 holding.
  • Covestor first reported a position in Ligand Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.